Clinical Trials
Open
Phase
Accrual
78%
SWOG Clinical Trial Number
S1501
Prospective Observational Cohort Study of Patients with Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Status Notes
Effective with the Status Notice distributed with the 11/1/24 SWOG broadcast, this study will be reactivated and open to participant accrual as of November 1, 2024 12PM PST.
For questions you may email the study team at: S1501question@swog.org
For questions you may email the study team at: S1501question@swog.org
Research Committee(s)
Palliative and End of Life Care Committee
Breast Cancer
Activated
09-15-2017
ClinicalTrials.gov Registry Number
NCT03418961
Closed
Phase
Accrual
82%
SWOG Clinical Trial Number
S1608
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Status Notes
Closed to accrual 7/15/24
Research Committee(s)
Lymphoma
Activated
08-10-2017
Closed
07-15-2024
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1616
A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) OR Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent
Research Committee(s)
Melanoma
Activated
07-17-2017
ClinicalTrials.gov Registry Number
NCT03033576
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1602
A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer
Status Notes
There is a monthly call for coordinators who have questions about this study. Send an email to S1602question@swog.org to be added.
Research Committee(s)
Genitourinary Cancer
Activated
02-07-2017
Closed
12-15-2020
ClinicalTrials.gov Registry Number
NCT03091660
Closed
Phase
Accrual
85%
SWOG Clinical Trial Number
S1400G
A PHASE II STUDY OF TALAZOPARIB FOR PREVIOUSLY TREATED HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY POSITIVE PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER (LUNG-MAP SUB-STUDY)
Status Notes
Effective July 23, 2018, S1400G will be permanently closed to accrual.
Effective 2:00 p.m. Pacific Time on June 20th, 2018, S1400G will be temporarily closed to accrual.
Effective 2:00 p.m. Pacific Time on February 7, 2017, S1400G will be open for patient accrual.
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Effective 2:00 p.m. Pacific Time on June 20th, 2018, S1400G will be temporarily closed to accrual.
Effective 2:00 p.m. Pacific Time on February 7, 2017, S1400G will be open for patient accrual.
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Lung Cancer
Activated
02-07-2017
Closed
07-23-2018
Closed
Phase
Accrual
85%
SWOG Clinical Trial Number
S1605
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Status Notes
NOTE: This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Genitourinary Cancer
Activated
02-07-2017
ClinicalTrials.gov Registry Number
NCT02844816
Closed
Phase
Accrual
98%
SWOG Clinical Trial Number
S1609
DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
Status Notes
Permanently Closed to Accrual: 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 41, 42, 43, 44, 45, 48, 51, 52, and 53.
Temporarily Closed to Accrual: 40, 46.
For the PD-L1 amplified cohort, patients do NOT need to qualify under one of the applicable histologies listed in Section 18.1.
Patients may now be registered directly to S1609 without having to be enrolled on EAY131 ("NCI-MATCH"). See Revision #3 for details.
Temporarily Closed to Accrual: 40, 46.
For the PD-L1 amplified cohort, patients do NOT need to qualify under one of the applicable histologies listed in Section 18.1.
Patients may now be registered directly to S1609 without having to be enrolled on EAY131 ("NCI-MATCH"). See Revision #3 for details.
Research Committee(s)
Early Therapeutics & Rare Cancers
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Lung Cancer
Melanoma
Activated
01-13-2017
Closed
03-15-2023
ClinicalTrials.gov Registry Number
02834013
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1512
A Phase II Study of PD-1 Blockade with Pembrolizumab In Patients with Locally Advanced and Metastatic Desmoplastic Melanoma (DM)
Status Notes
This study will permanently close to accrual, effective 6/4/21.
Research Committee(s)
Melanoma
Activated
10-20-2016
ClinicalTrials.gov Registry Number
NCT #02775851
Closed
Phase
Accrual
93%
SWOG Clinical Trial Number
S1415CD
A Pragmatic Trial To Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing, Effectiveness and Risk (TrACER)
Status Notes
This study was permanently closed to accrual effective 4/15/20.
Research Committee(s)
Cancer Care Delivery
Activated
10-07-2016
ClinicalTrials.gov Registry Number
NCT02728596
Closed
Phase
Accrual
86%
SWOG Clinical Trial Number
S1513
Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC- 737664) in Metastatic Pancreatic Cancer
Status Notes
Effective Immediately (12/13/2017) S1513 is permanently closed. Patients currently receiving ABT-888 (Veliparib) must discontinue the experimental treatment but may continue on FOLFIRI alone. Patients on both arms should continue study follow-up.
Research Committee(s)
Gastrointestinal Cancer
Activated
09-01-2016
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1507
A Phase II Trial Of Trametinib with Docetaxel in Patients with Kras Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies.
Status Notes
This study permanently closed to accrual on March 15, 2018.
Research Committee(s)
Lung Cancer
Activated
07-18-2016
Closed
03-15-2018
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1416
Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer (TNBC) and/or BRCA Mutation-Associated Breast Cancer, with or without Brain Metastases
Status Notes
S1416 is closed to accrual and treatment effective 12/31/2024.
Research Committee(s)
Breast Cancer
Activated
07-07-2016
Closed
06-15-2019
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1417CD
Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer
Research Committee(s)
Cancer Care Delivery
Gastrointestinal Cancer
Activated
04-15-2016
Closed
02-01-2019
ClinicalTrials.gov Registry Number
NCT02728804
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1500
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511])in Metastatic Papillary Renal Carcinoma (PAPMET)
Status Notes
Arms 3 and 4 of the study referenced above are permanently closed to accrual effective 12/5/18. Arms 1 and 2 are active to accrual effective 1/22/19.
Research Committee(s)
Genitourinary Cancer
Activated
04-05-2016
ClinicalTrials.gov Registry Number
NCT02761057
Closed
Phase
Accrual
79%
SWOG Clinical Trial Number
S1400I
A BIOMARKER-DRIVEN MASTER PROTOCOL FOR PREVIOUSLY TREATED SQUAMOUS CELL LUNG CANCER - A PHASE III RANDOMIZED STUDY OF NIVOLUMAB PLUS IPILIMUMAB VERSUS NIVOLUMAB FOR PREVIOUSLY TREATED PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER AND NO MATCHING BIOMARKER
Status Notes
Effective 3:00 p.m. Pacific Time on April 23, 2018, S1400I will be permanently closed to accrual.
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Lung Cancer
Activated
12-18-2015
Closed
04-23-2018
Closed
Phase
Accrual
98%
SWOG Clinical Trial Number
S1404
A Phase III Randomized Trial of Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High-Risk Resected Melanoma -
Status Notes
Step 2 (randomization) of the above-referenced study will be permanently closed to accrual effective November 2, 2017 at 11:59 p.m. Pacific Time.
Closure to Step 1 (prestudy screening) was effective August 15th.
NOTE: This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Closure to Step 1 (prestudy screening) was effective August 15th.
NOTE: This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Melanoma
Symptom Control and Quality of Life
Activated
10-15-2015
ClinicalTrials.gov Registry Number
NCT02506153
Closed
Phase
Accrual
98%
SWOG Clinical Trial Number
S1505
A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Status Notes
S1505 is now closed to accrual as of 04/20/2018.
Research Committee(s)
Gastrointestinal Cancer
Activated
10-12-2015
ClinicalTrials.gov Registry Number
NCT02562716
Closed
Phase
Accrual
29%
SWOG Clinical Trial Number
S1403
A Randomized Phase II Trial of Afatinib Plus Cetuximab Versus Afatinib Alone In Treatment-Naïve Patients With Advanced, EGFR Mutation Positive Non-Small Lung Cancer (NSCLC)
Status Notes
This study permanently closed to accrual effective April 23, 2018.
Research Committee(s)
Lung Cancer
Activated
03-25-2015
Closed
04-23-2018
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1316
Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction
Status Notes
Re-Activation - Effective 6/1/18
Research Committee(s)
Cancer Survivorship
Gastrointestinal Cancer
Activated
03-09-2015
ClinicalTrials.gov Registry Number
NCT02270450
Closed
Phase
Accrual
98%
SWOG Clinical Trial Number
S1318
A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia Chromosome Negative (Ph-) Acute Lymphocytic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dastainib-Sensitive Mutations or Kinase Fusions (DSMKF)
Research Committee(s)
Leukemia
Activated
01-12-2015
Closed
09-29-2021
ClinicalTrials.gov Registry Number
02143414